AMG 176 + itraconazole

AMG 176 + itraconazole is a **combination of two drugs**: AMG 176, a potent, selective, and orally bioavailable small molecule inhibitor targeting myeloid cell leukemia 1 (MCL1), and itraconazole, an antifungal agent belonging to the triazole class. AMG 176 suppresses the anti-apoptotic function of MCL1, a member of the BCL2 family often dysregulated in hematologic malignancies, thus promoting cancer cell apoptosis[1][2][3]. AMG 176 is under clinical investigation for hematologic cancers, including chronic lymphocytic leukemia (CLL), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML), both as monotherapy and in various combinations (notably with venetoclax or azacitidine)[1][3][5]. Itraconazole is an approved antifungal small molecule that inhibits ergosterol synthesis by blocking lanosterol 14α-demethylase. In oncology, itraconazole is also explored for its effects as a Hedgehog pathway inhibitor and potential to inhibit tumor angiogenesis. Although there are no trials or preclinical literature specifically describing the clinical use of AMG 176 together with itraconazole, such a combination may be of pharmacokinetic interest, given itraconazole’s potent inhibition of CYP3A4, the principal enzyme responsible for metabolizing many small molecule drugs (including some investigational agents like AMG 176).